NovoCure (NVCR) EBT Margin (2014 - 2026)
NovoCure (NVCR) posted quarterly EBT Margin of 6.78% for Q2 2026, up 1524.0% year-on-year from 0.42% in Q2 2025, and up 82.95% on a QoQ basis from 39.79% in Q1 2026.
NovoCure (NVCR) EBT Margin (2014 - 2026) Analysis & Trends
NovoCure (NVCR) has reported EBT Margin for 13 consecutive years, with 6.78% the latest figure, recorded in Q2 2026.
- Quarterly EBT Margin rose 1524.0% year-over-year to 6.78% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 21.84% (up 71.0% YoY) and the FY2025 annual result came in at 20.79%, up 88.0% from the prior year.
- EBT Margin advanced to 6.78% in Q2 2026 per NVCR's latest filing, from 39.79% in the prior quarter.
- Over the last five years, EBT Margin for NVCR reached as high as 1.83% in Q1 2022 and fell as low as 42.76% in Q2 2023.
- A 5-year average of 23.81% and a median of 22.44% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin sank 3998 bps — and 2024, when it surged 2765 bps.
- Year by year, EBT Margin stood at 25.35% in 2022, then declined by 14 bps to 28.8% in 2023, then dropped by 19 bps to 34.23% in 2024, then soared by 31 bps to 23.49% in 2025, then soared by 71 bps to 6.78% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 6.78%, 39.79%, and 23.49% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.98% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 14.12% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.70% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.33% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 27.84% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 22.61% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 4.87% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 9.84% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | NovoCure | 2.28 Bn | 1.85 Bn | 142.48 Mn | -6.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.78% |
| Mar 31, 2026 | -39.79% |
| Dec 31, 2025 | -23.49% |
| Sep 30, 2025 | -17.96% |
| Jun 30, 2025 | -22.03% |
| Mar 31, 2025 | -19.55% |
| Dec 31, 2024 | -34.23% |
| Sep 30, 2024 | -13.92% |
| Jun 30, 2024 | -15.12% |
| Mar 31, 2024 | -22.85% |
| Dec 31, 2023 | -28.80% |
| Sep 30, 2023 | -37.87% |
| Jun 30, 2023 | -42.76% |
| Mar 31, 2023 | -41.81% |
| Dec 31, 2022 | -25.35% |
| Sep 30, 2022 | -17.88% |
| Jun 30, 2022 | -16.58% |
| Mar 31, 2022 | -1.83% |
| Dec 31, 2021 | -19.20% |
| Sep 30, 2021 | -7.88% |